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Aims: Severe pulmonary arterial hypertension (PAH) is an incurable disease whose exact mechanisms remain
unknown. However, growing evidence highlights the role of inﬂammation and endothelin (ET) signaling. The
lack of reliablemodelsmakes it difﬁcult to investigate the pathophysiology of this disease. Our aimwas therefore
to develop a mouse model of severe PAH closely mimicking the human condition to explore the role of
interleukin-6 (IL-6), and ET signaling in advanced PAH progression.
Main methods: Youngmale SV129 mice received vascular endothelial growth factor receptor inhibitor (SU5416)
three times a week and were exposed to hypoxia (10% O2) for three weeks. Molecular analysis and histological
assessment were examined using real-time PCR, Western blot and immunostaining, respectively.
Key ﬁndings: The developedmurinemodel presented important characteristics of severe PAH in human: concen-
tric neointimal wall thickening, plexogenic lesions, recruitment of macrophages, and distal arteriolar wall
muscularization. We detected an increase of IL-6 production and a stronger macrophage recruitment in adven-
titia of remodeled arterioles developing plexogenic lesions. Moreover, ET-1 and ET receptor A were up-
regulated in lung lysates and media of remodeled arterioles. Recombinant IL-6 stimulated the proliferation and
regulated endothelial cells in increasing ET-1 and decreasing ET receptor B.
Signiﬁcance: These data describe a murine model, which displays the most important features of human severe
PAH. We assume that inﬂammation, particularly IL-6 regulating ET signaling, plays a crucial role in forming
plexogenic lesions. This model is thus reliable and might be used for a better understanding of severe PAH
progression and treatment.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3Introduction
Pulmonary artery hypertension (PAH) is featured by aberrant
inﬂammation, vasoconstriction and remodeling in small pulmonary ar-
teries (PA) (Voelkel and Tuder, 1997). PA high pressure induces right
ventricular (RV) hypertrophy, failure and ultimately death (Humbert
et al., 2004; Tuder et al., 2001b). Severe PAH is characterized by hyper-
proliferation of PA smooth muscle cells (SMCs) and endothelial cells
(ECs), creatingmedial and concentric neointimal thickening, and arteri-
olar lumens' obliteration, leading to plexogenic lesions (Pietra et al.,
2004; Tuder et al., 1994). Current therapies including prostacyclins,
endothelin receptor antagonists (ERA), and phosphodiesterase-5edicine, Department of Internal
5-1, Kusunoki, Chuo, Kobe 650-
9.
. This is an open access article underinhibitors, focus on pulmonary arterial endothelial cell (PAEC) dysfunc-
tions but not their hyperproliferation (Archer et al., 2010), hence,
the annual mortality is still up to 15% (Thenappan et al., 2007). This rel-
ative inefﬁcacy highlights a strong demand in animal modeling with
recapitulative pathophysiological changes of severe PAH.
Although the prognosis of patients with inﬂammation-associated
PAH (i.e. connective tissue disease- (CTD-) associated PAH, particularly
systemic sclerosis- (SSc-) associated PAH) improved recently, it is still
worse than that of idiopathic PAH (iPAH) (Condliffe et al., 2009; Fisher
et al., 2006; Girgis et al., 2005; Kawut et al., 2003). While inﬂammatory
disturbances are described in both iPAH and SSc-PAH, these aberrancies
aremore severe in SSc-PAH,which explains the clinical and outcomedis-
crepancies between the two syndromes (Fisher et al., 2006; Hassoun
et al., 2009; Kawut et al., 2003). This suggests an inappropriate control
of inﬂammation in the treatment of severe PAH.
Interleukin-6 (IL-6) concentration in patient plasma and lung tissues
correlates with the severity and prognosis of the disease (Soon et al.,
2010). IL-6 is elevated in most forms of PAH, especially CTD-PAHthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ .0/).3
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et al., 1998). Subcutaneous injection of recombinant IL-6 (rIL-6) in rats
(Miyata et al., 2001) and mice (Golembeski et al., 2005) induced PAH
determined by medial thickening of small PA, Fulton index and right
ventricular systolic pressure (RVSP), while IL-6 transgenic (IL-6 Tg+)
mice spontaneously developed PAH with neointimal hyperplasia
(Steiner et al., 2009). Moreover, IL-6 knockout mice were resistant to
increase RVSP under hypoxia (Savale et al., 2007). The role of IL-6 to
induce severe PAH by stimulating the proliferation of ECs and SMCs
(Steiner et al., 2009; Yao et al., 2006, 2007) to create severe PAH.
However, the source and mechanism of IL-6 at the injured sites
are questionable. In experimental PAH, increased inﬂammatory cells
around and in remodeled lesions are accompanied with elevated cyto-
kines/chemokines including IL-6 and monocyte chemotactic protein-1
(MCP-1). In those models, PAH can be reversed or prevented by an
anti-inﬂammation treatment (Burke et al., 2009; Mizuno et al., 2012;
Price et al., 2011). In PAH patients, macrophages accumulate around
the plexogenic lesions (Tuder et al., 1994). We therefore investigated
whether IL-6 produced by the recruited macrophages at the injured
sites promoted the development of arteriopathy and consequent severe
PAH.
Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor pro-
duced by ECs, acting via two receptors, endothelin receptor A (ETAR)
on SMCs and endothelin receptor B (ETBR) on both SMCs and ECs. In
PAH patients, plasma ET-1 is elevated and correlates with the severity
and prognosis of the disease (Rubens et al., 2001). Particularly, ET-1 is
overexpressed in PAECs and in plexogenic lesions (Giaid et al., 1993).
Hence, ERA became one of the three main types of drug in current
treatments. However, efﬁcacy of ERA is limited in patients with CTD-
PAH, especially SSc-PAH, which possesses a high level of inﬂammatory
components such as increased IL-6 production (Hassoun et al., 2009;
Itoh et al., 2006), revealing the governor role of inﬂammation in regulat-
ing several pathways including ET-1 in these patients. We therefore
have hypothesized that IL-6 may be upstream of the ET-1 system and
regulates ET-1 signaling in the severe PAH.
Materials and methods
Reagents
The following antibodies were used: puriﬁed rat-anti-mouse Mac-3
(cat. 550292), puriﬁed rat-anti-mouse CD31 (cat. 550274) (BD
Pharmingen), HIF-1α (cat. NB100-479) (Novus Biologicals), rabbit anti
PCNA (cat. ab29), rabbit anti IL-6 (cat. ab6672), rabbit anti VEGF-R2
(cat. ab2349) (Abcam), rat anti mouse F4/80 (cat. MCA 497GA) (AbD
Serotect), rabbit antibody von Willebrand factor (cat. A008202) (Dako
Glostrup, Denmark), phosphorylated Smad3 (pSmad3) (cat. 9134S)
(Cell Signaling), rabbit anti GAPDH (cat. G9545), αSMA (cat. A2547&
F3777) (Sigma), Bcl-2 (cat. sc-7383), phosphorylated extracellular
signal-regulated kinases (pERK1/2) (cat. sc-7383), C-Jun N-terminal
kinase (pJNK) (cat. sc-6254), JNK (cat. sc-571) (Santa Cruz), and
endothelin A receptor (ETAR) (cat. ARE-001) (Alemone Labs). Vascular
endothelial growth factor receptor (VEGF-R) inhibitor (SU5416)
(cat. 13342) was purchased from Cayman Chemical Co. Recombinant
human interleukin-6 (rhIL-6) (cat. 7270-IL-025/CF) was bought from
R&D Systems.
Experimental procedure for the development of a model of severe
mouse PAH
All animal procedures were performed in accordance with the
Guidelines for Animal Experimentation established by the Kobe Univer-
sity Graduate School of Medicine, Japan. Mice were kept in a roomwith
controlled temperature (22–24 °C) under a 12-hour-light–dark cycle.
Food and water were accessible ad libitum. The experimental design
was modiﬁed from that of Ciuclan et al. (2011). Brieﬂy, 3-week-oldmale SV129 wild-type mice (n = 5–6 each group) received 20 mg/kg
VEGF-R inhibitor (SU5416) (Hypoxia + SU), which was suspended in
CMC [0.5% (w/v) carboxymethylcellulose sodium, 0.9% (w/v) sodium
chloride, 0.4% (v/v) polysorbate 80, 0.9% (v/v) benzyl alcohol in deion-
ized water] or vehicle (CMC only) (Hypoxia) subcutaneously three
times a week and were exposed to chronic normobaric hypoxia (10%
O2) in a ventilated chamber for three weeks. The chamber was ﬂushed
with a mixture of room air and nitrogen and was opened on the alter-
nate day during 20 min for injection, hygiene and feeding reason. The
gas was recirculated. The hypoxic condition was monitored using an
oxygen monitor (Fujikura, Japan). Control mice (Normoxia) were kept
in the same room, under the same light–dark cycle.
Hemodynamic measurements
Each mouse was anesthetized by isoﬂurane (1.4 mg/kg) inhalation
via face mask. Isoﬂurane gas machine was connected to room air for
normoxic mice or hypoxic chamber for hypoxic and Hypoxia + SU
mice. To evaluate pulmonary arterial pressure (PAP), 10 min after
inhalant anesthesia, the right ventricle was assessed at subxiphoid site
by a percutaneously inserted 25G needle connected to a pressure trans-
ducer. Right ventricular systolic pressure (RVSP) and heart rate (HR)
were recorded on a Macintosh computer using the MacLab system
(Bioresearch Center). The results were exploited if the HR under these
conditions ranged between 300 and 500 beats per minute (bpm).
After hemodynamic measurements, the chest was opened and the
lung and heart were cleared of blood with phosphate buffered saline
(PBS) via RVusing 26Gneedle connected to a perfusionmachine in con-
stant pressure pump. Lung tissues were collected for histological and
molecular proﬁling. The heart was removed. The RV was dissected
from the left ventricle (LV) and septum (S), then the Fulton index
(RV/LV + S) and RV mass [RV (mg)/body weight (g) (BW)] were
determined.
Histology, immunohistochemistry (IHC) and immunoﬂuorescence (IF)
The right lung (RL) was removed after tight suturing at the hilus and
snap-frozen for molecular proﬁling assays. The left lung (LL) was inﬂat-
ed with 0.1 ml of 4% paraformaldehyde (PFA) through a cathlon 22G
inserted into trachea and pumped with constant pressure. Cathlon
was released and trachea was closely tied, then the LL was removed,
ﬁxed in 4% PFA overnight and processed into parafﬁn using a standard
procedure. Transverse section was performed to divide the LL into
four pieces which were arranged in sequence and embedded in the
same parafﬁn cassette and cut at 4 μm thickness. Five LLs in each
group and 8 sections of each lung were investigated.
Lung specimenswere de-parafﬁnized in a series of xylene baths. The
slides were then rehydrated in graded ethanol and distilled water. To
retrieve antigenicity, the tissue sections were incubated in trypsin
0.02% in 1× TBS for 8 min at 37 °C for IL-6 or heated using microwave
in 10 mM citrate buffer (pH 6.0) 15 min for the others.
For IHC
After cooling in room temperature (RT) for 30 min, the sections
were washed with PBS and immersed in PBS containing 3% hydrogen
peroxide (H2O2) for 5 min and blocked with 5% bovine serum albumin
(BSA) in PBS for 20 min. Primary antibodywas applied and incubated at
4 °C overnight. ForMac3 staining, slides were blocked in 0.3% H2O2/40%
methanol/PBS for 1 h at RT. Following PBSwashing, secondary antibody
was applied 1 h at RT. 3,3′-Diaminobenzidine (DAB)was used as a chro-
mogen (Dako, Carpinteria, CA).
For IF
The sections were washed with 0.05% Triton X in PBS (PBS-T) and
blocked with 3% BSA/PBS-T for 20 min. Primary antibody was used
at 4 °C overnight. Following PBS-T washing, secondary antibody was
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for nuclei staining. Slides were incubated in autoﬂuorescent-blocking
reagent (CuSO4) for 60 min and mounted.
Image analysis
Slides were examined using Keyence BIOZEROmicroscope (Keyence,
Osaka, Japan). Each group included 5 mice, 8 sections per mouse were
checked. In each section around 40 small PA (b100 μm diameter)
sections were blindly evaluated. For muscularization quantiﬁcation,
the intensity of muscularization of small PA was determined based on
the circumferential staining of α-smooth muscle actin (SMA) as either
non-muscularized (N) (when no or little SMA staining) or partially
muscularized (P) (when b75% SMA staining) or fully muscularized
(F) (when ≥ 75% SMA staining), then the percentage distribution of
each calculated per group. The results were the mean of all. For PCNA
quantiﬁcation, the number of PCNA positive cells on the endothelial
layer was manually scored. Macrophages were manually counted by
two independent investigators using 400× magniﬁcations. A minimum
of 40 ﬁelds/section or 40 small PA/section was examined. Results were
presented as mean of macrophages/ﬁeld or macrophages/vessel.
Quantitative real-time reverse transcription polymerase chain reaction
(RT-PCR)
Total mRNA was isolated from RL tissue using Trizol reagent
(Invitrogen) according to manual instruction and reversed transcribed
using ReverTra Ace (Toyobo). 10 ng cDNA was applied for real time
polymerase chain reaction (RT-PCR) using Thunderbird SYBR qPCR
Mix (Toyobo) with the Rotor-Gene Q Real Time PCR Systems (Qiagen,
Germany). Speciﬁcity of ampliﬁedRT-PCRproductwas veriﬁed bymelt-
ing curve analysis or agarose gel electrophoresis. Relative mRNA levels
were analyzed with a quantitative comparative Ct method and normal-
ized with GAPDH or 18S gene expression as internal control. The
primers used in this experiments were listed in Table 1.
Immunoblotting
Frozen RLswereminced and homogenized in RIPA buffer containing
protease inhibitor cocktail. The lysates were eluted with 1× Laemmli
buffer and resolved on SDS-PAGE gel, transferred to Immobilon
polyvinylidene diﬂuoride membrane (Millipore, Bedford, MA). Mem-
branes were blocked with 5% skim milk in Tris-buffered saline–Tween
20 (TBS–T) at RT for 1 h and incubated with the primary antibody in
Can Get Signal solution (Toyobo) at 4 °C overnight. Membranes were
then washed 3 times with 1× TBS–T and incubated with the 2nd anti-
body in Can Get Signal solution for 1 h at RT. The band was detected
by using the Luminata Forte Western HRP Substrate (Millipore) and
luminescence was observed on an ImageQuant LAS 4000 (GE, Japan).Table 1
List of primers.
Gene Forward primers (5′–3′) Reverse primers (5′–3′)
mMCP1 GCATCCACGTGTTGGCTCA CTCCAGCCTACTCATTGGGATCA
mGAPDH TGTGTCCGTCGTGGATCTGA TTGCTGTTGAAGTCGCAGGAG
mBMPRII GAGCCCTCCCTTGACCTG GTATCGACCCCGTCCAATC
mIL-6 GCTACCAAACTGGATATAATCAGGA CCAGGTAGCTATGGTACTCCAGAA
mIL-6R ATCCTCTGGAACCCCACAC GAACTTTCGTACTGATCCTCGTG
mMMP-9 GCCTGGCACATAGTAGGCCC CTTCCTAGCCAGCCGGCATC
mETBR CATGCGCAATGGTCCCAATA GCTCCAAATGGCCAGTCCTC
mETAR GCTGGTTCCCTCTTCACTTAAGC TCATGGTTGCCAGGTTAATGC
mET-1 GCCACAGACCAGGCAGTTAGA CACCAGCTGCTGATAGATACACTTC
mBcl-2 GTGTTCCATGCACCAAGTCCA AGGTACAGGCATTGCCGCATA
mVEGF-A CAGTTCGAGGAAAGGGAAAGG CACGTCTGCGGATCTTGGAC
mVEGF-R2 CCTACCTCACCTGTTTCCTGTATG ACCATCCCACTGTCTGTCTGG
mTGF-β TTCCGCTGCTACTGCAAGTCA GGGTAGCGATCGAGTGTCCA
h18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
hIL-6 TTCGGTCCAGTTGCCTTCTC GAGGTGAGTGGCTGTCTGTGThe membranes were then stripped with a solution containing SDS 1%
and glycine 0.2% (pH = 2) for 45 min at 50 °C and GAPDHwas stained.
Bands were quantiﬁed with AlphaEaseFC software (Alpha Innotech
Corporation) and normalized with GAPDH.
Generating of primary pulmonary endothelial cells (pmPECs)
Preparation of antibody-coated beads
Sheep anti-rat IgGDynabeads (cat. 110.35) (Invitrogen)waswashed
6 times with sterile 0.1% BSA/PBS and resuspended at 80 millions
beads/ml. Each wash was performed by sitting the beads on magnetic
particle concentrator (MPC) (DynaMg-2 cat. 12321D) (Invitrogen) for
1 min to allow the beads to sediment. Beads were then saturated with
10 μl of Puriﬁed Rat-anti Mouse CD31 (CD-31) antibody. Coating was
performed on a rotator standing at RT for 2 h. Beads were then washed
5 times as described above and resuspended in 200 μl 0.1% BSA/PBS.
Magnetic bead sorting to isolate endothelial cells from young murine lung
Each 3 week-old mouse was anesthetized with pentobarbital
(Kyoritsu-Seiyaku, Tokyo, Japan) and the thoracic cavity was assessed.
The individual lung lobes (without the bronchi and surrounding con-
nective tissue) were aseptically excised and immersed in ice-cold
DMEM. The lobes were removed from the DMEM, ﬁnely minced by
cutting around 100 times and then incubated with 15 ml warm 0.1%
collagenase/dispase solution in DMEM for enzymatic digestion for
45 min at 37 °C on a rotator. After the 45 min incubation, the digested
tissue suspension was transferred into a 20 ml syringe attached to
a 14G cannula and homogenized around 12 times into a single cell sus-
pension. The resulting cell suspension was ﬁltered through a 40-μm
strainer and washed with 15 ml isolation media (IM) (20% FBS/DMEM
and 1× Penicillin/Streptomycin) to stop digestion. The ﬁltered cell sus-
pension was centrifuged for 5 min at 400 g. After the removal of the
supernatant, the cell pellet was resuspended in 3 ml 0.1% BSA/PBS;
22.5 μl prepared magnetic beads coated with anti-CD31 antibodies
was added and mixed at RT for 12 min. The bead was then sedimented
using theMPC for 1 min. After removal of the supernatant, the cell pellet
was washed 5 times with 3 ml of 0.1% BSA/PBS, each time remounted
on the MPC and then resuspended and mixed well in 3 ml of HuMedia
EG2 medium (cat. KE-2510S) (Kurabo, Japan) with FBS 2% and growth
factors and 1× penicillin/streptomycin (VL) and plated into a 2%
gelatin-coated 10 cm disk. Total volume was brought to 10 ml with VL
in each disk. The alternating day, half of the medium was changed.
The cells were cultured for an additional of 3–4 days to reach 70–80%
conﬂuence.
Resorting with magnetic beads coated anti-CD31 antibodies
At the conﬂuence of 70 to 80%, the cells were detached by 0.05%
trypsin/EDTA for 3 min. When cells were completely detached, 2 ml
of IM was added to inhibit trypsinization. Cell suspension was spin
down for 5 min at 400 g and cell pellet was resuspended in 2 ml 0.1%
BSA/PBS. 10 μl prepared magnetic beads coated with anti-CD31 anti-
bodies was added and rotated at room temperature for 12 min. Cells
were washed 5 times with 0.1% BSA/PBS, each time mounted on MPC.
Cells were then plated into a 2% gelatin-coated 10 cm disk. The purity
of pmPECs was determined using double immunoﬂuorescent staining
for CD31 and S100A4 (ﬁbroblast marker).
Cell culture
Activated macrophages transformed from human monocytic cell
line (THP-1 cat. RCB1189) and mouse pancreatic endothelial cell line
(MS1) were obtained from RIKEN Cell Bank and cultured at 37 °C (5%
CO2 and 95% air). THP-1 was cultured in RPMI Medium 1640 (Gibco)
with 10% FBS. The experiment in vitro was carried out by culturing
humanmacrophages transformed from THP-1 under phorbol myristate
acetate treatment (PMA) and then treating them in hypoxia (1% O2)
Table 2
Baseline bodyweight,ﬁnal bodyweight, and heart rate after injection of SU5416 or vehicle
and exposure for 3 weeks to 10% O2 (hypoxia) or room air (normoxia).
Normoxia Hypoxia Hypoxia + SU
n = 6 n = 6 n = 5
Baseline body weight (g) 9.58 ± 0.37 9.72 ± 0.27 9.92 ± 0.21
Final body weight (g) 19.90 ± 0.72 18.80 ± 0.57 17.23 ± 0.49 A, B
Heart rate (bmp) 370 ± 15 383 ± 20 392 ± 23
All values are the mean ± SEM. A: P b 0.01 versus normoxia and B: P b 0.05 versus
hypoxia.
Heart rate: measured while recording right ventricular systolic pressure (RVSP).
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and mRNA and protein IL-6 expression were checked. MS1 cells were
cultured in complete medium consisting DMEM/high glucose (cat.
D5796) (Sigma) with 10% FBS. pmPECs were established in the lab as
stated above and cultured with VL medium. The cells were subcultured
by 0.05% trypsin (Gibco). MS1 cells and pmPECs were subjected to
50 ng/ml IL-6 treatment for 24 h. The cells were collected and mRNA
expression of ET-1 and ETBR were checked.
Proliferation assay
To assess the cell viability, MS1 were seeded at a concentration
at 1 × 104 cells/well (96-well plate) and cultured in an incubator
(5% CO2 and at 37 °C) in a normal medium as describe above. 24 h
after seeding, the cells were starved using DMEM/high glucose 0.2%
FBS during 24 h. The cells were then treated with 50 ng/ml IL-6 for
24 h. The cell viability was examined using the Cell Counting Kit WST-
1 (cat. 345-06463) (Dojindo) according to the manufacturer's protocol.
Brieﬂy 10 μl of cell counting solution was added to each well, mixed
and the cells were reincubated in the incubator (5% CO2 and at 37 °C).
The formazan-dyes were detected by measuring the absorbance at
450 nm (reference wavelength 655 nm) after 1 h, 2 h and 4 h.
Data analysis
Results are presented as themean ± SEM. The data distributionwas
tested using Kolmogorov–Smirnov test. Normally distributed variables
were analyzed by using an unpaired Student t test for direct 2-group
comparisons and the post hoc Turkey test after a signiﬁcant 1-way
ANOVA F test for 3-group comparisons to identify which group differ-
ences accounted for signiﬁcant overall ANOVA results. Variables not
normally distributed were analyzed using nonparametric analysis
with Kruskal–Wallis followed byMann–Whitney U test. Statistical anal-
ysis was performed with the GraphPad Prism software package.
P b 0.05 was considered signiﬁcant.
Results
Experimental model of severe PAH
SU5416 aggravated the elevated PAP and RV hypertrophy created by
hypoxic condition
The murine model of severe PAH has been established by Ciuclan
et al. (2011) by treating adult C57/Bl6 mice with SU5416 in chronic
hypoxic environment. However, others have failed to reproduce this
model (Gomez-Arroyo et al., 2012). Therefore, we aimed to modify
the procedure by using young SV129 mice with higher frequency of
treatment with SU5416. After 3 weeks, a clear decrease in body weight
was observed in Hypoxia + SU mice in comparison with Hypoxia
(P b 0.05) and Normoxia (P b 0.01) mice. There was no signiﬁcant
difference between hypoxic and normoxic mice (Table 2).
We observed an upregulation of cleaved caspase-3 in Hypoxia + SU
group (P b 0.01 vs. Normoxia or Hypoxia), indicating an increased apo-
ptosis (Fig. 1B). Chronic hypoxia induced the elevation of RVSP in mice
with either SU5416 or vehicle, comparedwith themiceunderNormoxia
(RVSP = 37 mm Hg; 29 mm Hg and 22.5 mm Hg; respectively). Im-
portantly, treating with SU5416 induced a further increase of RVSP
(Fig. 1C). A RV hypertrophy was noted in Hypoxia (Fulton index, 0.40;
RV/BW, 1.3; P b 0.01 vs. normoxia, 0.31; 1.1) and was further elevated
inHypoxia + SU (Fulton index, 0.55; RV/BW, 1.8; P b 0.001 vs. Hypoxia)
(Fig. 1D, E).
SU5416 augmented the muscularization of distal acinar arterioles and the
thickening of arteriolar medial layer generated by hypoxia
One characteristic of PAH is the muscularization of distal acinar
arterioles. While the majority of normal lung small vessels was non-muscularized (N) (68%) and only a small number of fully muscularized
(F) was noted (12%), Hypoxia and Hypoxia + SUmice showed a reduc-
tion in N percentage (53% and 32%, respectively), along with the eleva-
tion of F percentage (24% and 42%, respectively) after 3 weeks.
Combination of SU5416 and hypoxia profoundly enhanced the degree
of F (P b 0.0001 vs. Hypoxia) and decreased the level of N (P b 0.0001
vs. Hypoxia) (Fig. 2B).
Only SU5416 combined with hypoxia can cause plexogenic lesions
To investigate the remodeling of small PA, we performed IHC of von
Willebrand factor (vWF), an endothelial cellmarker and double IF stain-
ing for vWF and SMA (Fig. 2A). Histological examination revealed vari-
ous degrees of concentric neointimal thickness in pulmonary arterioles,
particularly the complete lumen obliteration by multiple layers of cells
expressing vWF in Hypoxia + SU group (Fig. 2Ac,f). On the contrary,
no neointimal thickening lesions were observed and the endothelium
stillmaintainedmonolayer in hypoxic andnormoxicmice (Fig. 2Ab,d,e).
Proliferative endothelial cells completely occluded the small lung arteries in
hypoxia combined SU5416-treated mice
To demonstrate whether the cells expressing vWF in plexogenic
lesions were proliferating cells, we performed double IF staining for
the proliferation marker proliferating-cell nuclear antigen (PCNA) and
vWF. Cells expressing vWF in neointimal thickening lesions in pulmo-
nary arterioles of Hypoxia + SU mice remarkably up-regulated PCNA
contributing to plexogenic lesion formation (Fig. 3Ac), whereas, that
of hypoxic and normoxic mice exhibited minimal PCNA expression
(Fig. 3Aa,b). A three time increase in the amount of PCNA positive
cells in endothelium of remodeled arterioles was noted in Hypoxia +
SU compared with Hypoxia and Normoxia (P b 0.001), whereas no sig-
niﬁcant difference between hypoxic and normoxic mice (Fig. 3B).
Alteration of biomarkers, inﬂammatory proﬁles and signaling pathways in
hypoxia combined SU5416-treated group
Biomarker analysis revealed that angio-occlusion in SU5416-treated mice
under hypoxia was the consequence of hyper-proliferation and resistance
to apoptosis
Since it has been previously showed that exposure to chronic hyp-
oxia combined with VEGF-R inhibitor could generate an endothelial
population which escaped from the apoptosis and became aberrantly
proliferative (Taraseviciene-Stewart et al., 2001, 2006), we sought to
investigate this phenomenon in Hypoxia combined SU5416-treated
mouse model. VEGF-A mRNA was elevated in Hypoxia alone (P b 0.01
vs. Normoxia) and further enhanced in Hypoxia + SU (P b 0.05 vs.
Hypoxia) (Fig. 3D). VEGF-R2 mRNA and protein levels were up-
regulated in Hypoxia + SU (P b 0.01 vs. Normoxia) (Fig. 3E, F), but
were not enhanced in mice under hypoxia only (Fig. 3E, F). mRNA of
MMP-9 was increased in the hypoxic group (P b 0.01 vs. Normoxia)
and further induced in Hypoxia + SU group (P b 0.05 vs. Hypoxia)
(Fig. 3C). In addition, we assessed the expression of pJNK and pERK1/
2, which are known as growing factors for PAECs. Protein level of pJNK
and pERK1/2 in the lung lysates were remarkably raised in Hypoxia +
SU-treated mice (P b 0.05 vs. Hypoxia), while exposure to hypoxia
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Fig. 1.Effect of vascular endothelial growth factor receptor (VEGFR) inhibitor (SU5416)on lung vessels. (A) Experimental setup: three-week-oldmale SV129micewere injected subcutaneously
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317T. Van Hung et al. / Life Sciences 118 (2014) 313–328only had no potent effect (Fig. 3I, J). Furthermore, quantitative RT-PCR
and immunoblot were performed for Bcl-2, an anti-apoptotic marker.
Only Hypoxia + SU could increase mRNA and protein levels of Bcl-2
(P b 0.05 vs. Hypoxia) (Fig. 3G, H).
Inﬂammatory proﬁle altered in response to hypoxia with/without VEGF-R
inhibition
To explore the possibility that inﬂammatory cell inﬁltration may
contribute to the formation of neointimal thickening and occluded arte-
rioles, we performed IHC for Mac3 antibody, a macrophagemarker, and
quantiﬁed the number of macrophages in the lungs and in the adventi-
tia of lung arterioles. Hypoxia induced recruitment of macrophages to
the lungs and the adventitia of arterioles (P b 0.01 vs Normoxia)
(Fig. 4Aa,b,d,e; B; C). Hypoxia + SU further increased these numbers
two to three times (P b 0.0001 vs. Hypoxia) (Fig. 4Ab,c,e,f; B; C). The
results were supported by Western blot data that F4/80 expression in
lung lysates signiﬁcantly enhanced under hypoxic exposure (P b 0.05
vs. Normoxia) and three times greater in hypoxia combined with
SU5416 treatment (P b 0.01 vs. Hypoxia) (Fig. 4D). Moreover, mono-
cyte chemotactic protein-1 (MCP-1), an important chemokine in
recruitment and activation of macrophages, was also profoundly up-
regulated in Hypoxia + SU only (P b 0.001 vs. Hypoxia and Normoxia)
(Fig. 4E).
IL-6 and its receptor were elevated in the lungs under hypoxia combined
SU5416 treatment
To investigate the role of recruited macrophages in the adventitia
of remodeled arterioles in the formation of plexogenic lesions, weconcentrated on proinﬂammatory cytokine IL-6, being well known as
one of themost important cytokines associatedwith PAH development.
IHC (Fig. 5Aa–c) and double IF staining (Fig. 5Ad–i) were carried out for
IL-6 or IL-6 and SMA, respectively. Combination of SU5416 and chronic
hypoxia induced abundant IL-6 in the adventitia of remodeled arterioles
(Fig. 5Ac,f,i), whereas, hypoxia alone only generatedminimal expression
(Fig. 5Ab,e,h). No detectable signal was observed in normoxic mice
(Fig. 5Aa,d,g). Immunoblot and quantitative RT-PCR also conﬁrmed
the greater up-regulation of protein and mRNA IL-6 in Hypoxia + SU
(P b 0.001 and P b 0.05 vs. Hypoxia, respectively), while no signiﬁcant
increase was observed in hypoxic mice (P = 0.3 and 0.14, vs. Normoxia,
respectively) (Fig. 5B, C). Similarly, IL-6 receptormRNAwas signiﬁcantly
raised in Hypoxia + SUmice (P b 0.05 vs. Hypoxia and Normoxia) only
(Fig. 5D).
Hypoxia inducible factor (HIF-1α) signaling machinery, transforming
growth factor β (TGF-β)/bone morphogenic protein (BMP)/Smad axis
was perturbed in mice exposed to hypoxia combined with/without SU5416
AsHIF-1α is known to be elevated in lung of patientswith idiopathic
PAH, we aimed to determine HIF-1α level. Western blot results de-
scribed a marked elevation of HIF-1α protein in the lung of hypoxic
mice (P b 0.05 vs. Normoxia) and this effect was further increased
in Hypoxia + SU group (P b 0.01 vs. Hypoxia) (Fig. 6A). We assessed
the gene expression of TGF-β/BMP/Smad axis. TGF-β mRNA was up-
regulated under hypoxic exposure (P b 0.05 vs. Normoxia), with no
further inﬂuence created by SU5416 combination (Fig. 6C). In contrast,
protein level of phosphorylated Smad3, downstream component of
TGF-β signaling which modulated cellular response linked to vascular
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Fig. 2. SU5416 enhanced chronic hypoxia-induced vascular remodeling with development of neointimal occlusive lesions. (A) (a–f) Representative double immunoﬂuorescent (a–c) and
immunohistochemistry (d–f) staining images of the predominantly remodeled vessel showed completely occluded arterioles withmultilayer of cells expressing vWF and severe thicken-
ing ofmedial layer of arterioles in hypoxia combined SU5416-treatedmice (c, f). No neointimal hyperplastic or occlusive lesionswere noted and endothelium still remainedmonolayer in
hypoxic and normoxic mice (a, b, d, e). Medial layer was thicker in hypoxic mice (b, e), but thinner than in hypoxia combined SU5416-treated mice (c, f). (B) Vascular muscularization:
4-μm lung sectionswere stainedwith antibodies forα-smoothmuscle actin (SMA) and vonWillebrand factor (vWF). Forty pulmonary arterioles (b100 μm) per sectionwere blindly eval-
uated to the source of tissue. Based on the circumferential staining of SMA, the vessel was determined as either non-muscularized (N), or partially muscularized (P) (b75% staining), or
fully muscularized (F) (≥75% staining), then the percentage distribution of each calculated per group. Scale bars: 50 μm. Statistical differences (***P b 0.001, ****P b 0.0001) were
expressed by analysis of variance.
318 T. Van Hung et al. / Life Sciences 118 (2014) 313–328remodeling, was slightly elevated in hypoxic treatment (P = 0.4 vs.
Normoxia) but six times greater promoted in Hypoxia + SU (P b 0.05)
(Fig. 6B). A signiﬁcant reduction in BMPRII mRNA expression was
noted in hypoxic mice (P b 0.05 vs. Normoxia), with no advanced effect
in Hypoxia + SU mice (Fig. 6D).
Disturbance in endothelin pathway under combination of chronic hypoxia
and VEGF-R inhibition
Therewas an increase in ET-1 and ETARmRNA (P b 0.01 vs. Hypoxia
and Normoxia) (Fig. 7A, B) and a reduction in ETBRmRNA (P b 0.05 vs.
Hypoxia; P b 0.01 vs. Normoxia) (Fig. 7D) under combination treat-
ment of hypoxia and SU5416, while, no inﬂuence of hypoxic treatment
was noted in ET-1, ETAR and ETBRmRNA levels (Fig. 7A, B, D). Similarly,
ETAR protein was augmented in Hypoxia + SU-treated mice only
(Fig. 7C). Interestingly, immunostaining results depicted a colocalization
of ETAR (red) and SMA (green) in the media of arterioles in Hypoxia +SU-treated mice only (Fig. 7Ec,f). No colocalized signal in hypoxic and
normoxic mice was recorded (Fig. 7Ea,b,d,e).
In vitro inﬂuence of Hypoxia combinedwith SU5416 on IL-6 expression and
effect of IL-6 on endothelin signaling pathway
Hypoxia combined with SU5416 promoted IL-6 expression in human
macrophages
In cultured humanmacrophages, IL-6 mRNA and protein expression
were increased in Hypoxia + SU-treated cells (P b 0.05 vs. Hypoxia;
P b 0.01 vs. Normoxia), while exposure to hypoxia only enhanced
slightly IL-6 protein (P = 0.2 vs. Normoxia) (Fig. 8).
Recombinant human IL-6 stimulated the proliferation and regulated ECs in
increasing ET-1 and decreasing ETBR expression
In MS1 and pmPECs, IL-6 treatment (50 ng/ml) increased ET-1
mRNA (P b 0.05 vs. controls) and reduced mRNA ETBR expression
319T. Van Hung et al. / Life Sciences 118 (2014) 313–328(P b 0.05; P b 0.01 vs. controls in MS1 and in pmPECs, respectively)
(Fig. 9). IL-6 treatment enhanced proliferation of MS1 cells (P b 0.001
vs. controls) detected by WST-1 assay (Fig. 9C).
Discussion
The newly optimized mouse model of severe PAH
The hallmark of severe PAH patients is the remodeling in small lung
vessels characterized by concentric neointimal thickening, plexogenic
lesions, recruitment of inﬂammatory cells, and distal arteriolar wall
muscularization (Tuder et al., 1994). To date, several rat models of
severe PAH closelymimicking human conditions have been established.HypoNormoxiaA
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Fig. 3. Hypoxia combined SU5416 induced endothelial cellular proliferation. (A) Representativ
with increasing Proliferating Cell Nuclear Antigen (PCNA) expression in the thicken endothe
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(*P b0.05, **P b 0.01, ***P b 0.001) were determined using t test.The closest one combines hypoxia with a SU5416 treatment (Abe et al.,
2010; Taraseviciene-Stewart et al., 2001). However, this model could
not provoke the inﬂammatory response in the rat lung (Abe et al.,
2010; Taraseviciene-Stewart et al., 2001), a common phenomenon
observed in patients (Cool et al., 1997; Hall et al., 2009; Pinto et al.,
2004; Tuder et al., 1994). It might explain the discrepancy in application
of several drugs such as simvastatin (Taraseviciene-Stewart et al.,
2006), which provides a good recovery in the rat model, yet shows no
beneﬁcial effects in humans (Kawut et al., 2011). Problems have
occurred in establishing the severe PAH inmouse, the common alterna-
tive to rats as laboratory animals. First, mice are less vulnerable to hyp-
oxia than rats regarding pulmonary vessel remodeling (Dempsey et al.,
2009; Frank et al., 2008; Nozik-Grayck et al., 2008). Hypoxia inducesHypoxia+SUxia
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320 T. Van Hung et al. / Life Sciences 118 (2014) 313–328genes involved in EC proliferation in rats but not in mice (Hoshikawa
et al., 2003). Second, the accumulation of SU5416 in lungs is less
in mice. Higher systemic and renal clearance of SU5416 in mice
was noted and SU5416 is hepatically metabolized by CYP450-1A, acytochrome distinctly expressed in animal species (Martignoni et al.,
2006; Nelson et al., 2004; Ye et al., 2006). Repeated administration of
SU5416 induces several CYP450 in the liver, which differ between the
two species (Craft et al., 2002; Martignoni et al., 2006). Ciuclan et al.
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Fig. 4. Increase of inﬂammatory response in hypoxia combined SU5416-treated mice versus in hypoxic and normoxic mice. (A) Representative immunohistochemistry staining images
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321T. Van Hung et al. / Life Sciences 118 (2014) 313–328successfully generated the severe PAH model from adult C57/Bl6 mice
(Ciuclan et al., 2011). However, this protocol could not be reproduced
in other workplaces (Gomez-Arroyo et al., 2012). Different mouse
strains may react differently and younger mice with rapidly maturinglungs are more vulnerable when exposed to hypoxia (Stenmark et al.,
2006). We thus used young SV129 mice, which were provenmore sen-
sitive to hypoxia than C57/Bl6 (Tada et al., 2008), and increased the fre-
quency of SU5416 treatment.
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322 T. Van Hung et al. / Life Sciences 118 (2014) 313–328Consistent with previous reports about the role of SU5416 in induc-
ing a sustained death of pulmonary ECs (Ciuclan et al., 2011; Sakao et al.,
2005; Taraseviciene-Stewart et al., 2001), we observed a markedincrease of cleaved caspase-3 in ourmodel. Hypoxia-induced inﬂamma-
tion (Burke et al., 2009; Savale et al., 2009) together with the apoptotic
bodies from apoptotic ECs may stimulate the release of IL-6 and MCP-1
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323T. Van Hung et al. / Life Sciences 118 (2014) 313–328(Berda-Haddad et al., 2011; Curtis et al., 2009), which in turn, may
recruit macrophages in the injured vessels, which might ultimately
lead to the development of severe PAH.
IL-6 as a potential conductor in severe PAH
IL-6, an important proinﬂammatory cytokine in PAH progression, is
produced by activated macrophages, ﬁbroblasts, ECs and SMCs. Indeed,
IL-6 is steadily increased and considered prognosis factor in idiopathic
and inﬂammation-associated PAH (Humbert et al., 1995; Li et al.,
2012; Nishimaki et al., 1999; Soon et al., 2010). Our study demonstrated
an up-regulation of IL-6 in Hypoxia + SU, especially an abundance of
IL-6 in the adventitia of remodeled arterioles. Consistently, IL-6 elevates
in and around the angio-obliterating lesions in SU + ovalbumin rat
PAHmodel (Mizuno et al., 2012). It is possible that IL-6 per semay stim-
ulate the proliferation of SMCs and ECs (Steiner et al., 2009; Yao et al.,
2006, 2007), and consequently form medial and concentric neointimal
thickening and plexogenic lesions, the ﬁngerprints of severe PAH
(Tuder et al., 1994). Our experiments conﬁrmed this idea by showing
that 50 ng/ml IL-6 stimulated the MS1 cell growth in vitro. IL-6 triggers
ECs at a dose dependent manner, i.e. ≥50 ng/ml IL-6 render cerebral
ECs proliferative, but 25 ng/ml IL-6 do not (Yao et al., 2006). In vivo,
even though IL-6 is slightly elevated in hypoxic mice, neither arteriolar
obliteration nor proliferative ECs was observed. This is consistent with
previous studies indicating that hypoxia alone cannot generate prolifer-
ation of ECs (Steiner et al., 2009; Voelkel and Tuder, 2000; Yu andHales,
2011). Hypoxia creates only a short-course raise of IL-6 peaking at day
7th and returning to the baseline at day 14th (Savale et al., 2007). IL-6
Tg+ mice also display most important features of severe PAH underhypoxia (Steiner et al., 2009). However, transgenic models do not fully
mirror the human condition. In this model, the authors show that IL-6
genetic overexpression induced PAH is worsened by hypoxia. The IL-6
expression levels however were not measured, which makes difﬁcult
to establish how strong the development of PAH correlates with IL-6
or with hypoxia. Moreover, it is not clear whether IL-6 produced by
Clara cells affects PA remodeling by directly targeting vessel wall cells
or by indirect effects mediated by inﬂammatory cells themselves. In
the present study, we have shown that the worsening of the PAH by
SU5416 treatment is associated with an increased expression of IL-6.
Ciuclan et al. depicted an elevation of mRNA IL-6 and macrophages in
the lung of their model, too (Ciuclan et al., 2011). Nevertheless, no rela-
tionship between macrophages, IL-6 and arteriolar remodeling had
been cited. Using Mac3 marker, we described an accumulation of mac-
rophages in the similar areas of IL-6 expression, which suggested that
IL-6 may be secreted from adventitial macrophages of remodeled arte-
rioles. This data was supported by our work in vitro indicating that
macrophages produced increased IL-6 under hypoxia combined with
SU5416.
Enormous inﬁltration of macrophages is often mentioned within
and around the remodeled arterioles in severe PAH. Macrophages
directly release MMP-9 (Mautino et al., 1999) and MCP-1 (Yoo et al.,
2005; Yoshimura et al., 1989), which, as a positive feedback, recruit
macrophages (Taylor et al., 2006). In mice, combination of MMP-9
overexpression and monocrotaline administration generates PAH with
occluded precapillary vessels and sustained macrophage inﬁltration
(George et al., 2012). In vitro, increased MMP-9 by IL-6 causes ECs
and SMCs to proliferate (Yao et al., 2006, 2007). MCP-1 is depicted in
ECs, SMCs, and macrophages within remodeled arterioles and closely
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325T. Van Hung et al. / Life Sciences 118 (2014) 313–328associatedwith pulmonary vascular resistance in PAH patients (Kimura
et al., 2001). MMP-9 and MCP-1 are also secreted by ECs (Genersch
et al., 2000; Kimura et al., 2001; Sanchez et al., 2007; Yao et al., 2006)
in PAH. Therefore, their high level in Hypoxia + SU may result from
the overproduction of proliferative ECs, which in turn contributing to
the recruitment and migration of macrophages (Sanchez et al., 2007).
IL-6moderates hyperproliferation and anti-apoptosis of ECs through
VEGF,MAPK signaling and Bcl-2. VEGF and VEGF-R2 are the key compo-
nents for EC survival and high levels of them have been found in the
lung, particularly in plexogenic lesions of PAH patients (Tuder et al.,
1994). VEGF and VEGF-R2 are up-regulated by IL-6 and trigger prolifer-
ation of ECs via pERK1/2. Consistently, blocking VEGF or VEGF-R2 abol-
ishes IL-6-induced proliferation (Steiner et al., 2009; Yao et al., 2006).
JNK, another MAPK component, is not only an anti-apoptosis but a pro-
liferative factor as well (Ma et al., 2012). Activation of pJNK induces
prosurvival signaling in ECs (Salameh et al., 2005), increases the prolif-
eration and decreases the apoptosis of bovine PAECs (Ma et al., 2012).BA ET-1
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Fig. 9. Effect of IL-6 treatment (50 ng/ml) on ET-1, ETBR expression and proliferation of MS1
(pmPECs). (A, B, D, E) Relative mRNA expression of ET-1, ETBR to GAPDH in MS1 (A, B) and p
WST-1 assay.We therefore examined protein levels of VEGF-R2, pERK1/2 and pJNK
in our model and recorded the elevation of all these parameters in
Hypoxia + SU. In PAH patients, Bcl-2 is increased in the lungs (Geraci
et al., 2001) and in PAECs associated with irreversibility of the disease
(Lévy et al., 2007). Furthermore, Bcl-2 is increased in IL-6 Tg+ mice
(Steiner et al., 2009) and induced by VEGF in serum-starved ECs (Cai
et al., 2003; Gerber et al., 1998). In our model, Bcl-2 could be indirectly
induced by IL-6 through VEGF to create an overproliferative EC
population.
HIF-1α, another IL-6-regulated factor, is highly expressed in angio-
obliterative proliferative lesions in PAH patients (Tuder et al., 2001a).
We noted a positive correlation between IL-6 and HIF-1α in Hypoxia
and Hypoxia + SU, while no association between them was observed
in Ciuclan's study (Ciuclan et al., 2011). The further augmentation
of HIF-1α in Hypoxic + SU mice may be partly induced by the activa-
tion of IL-6/Stat3/HIF-1α axis, an important pathway in cancer cells
(Grivennikov et al., 2009; Lang et al., 2007; Nilsson et al., 2010), andEC proliferationCETBR
BR
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mPECs (D, E) normalized to control. (C) IL-6 stimulated MS1 proliferation measured by
326 T. Van Hung et al. / Life Sciences 118 (2014) 313–328mentioned in rats with severe PAH (Mizuno et al., 2012). IL-6 triggers
phosphorylation of Stat3 (Heikkila et al., 2008), leading to up-
regulation of HIF-1α either by blocking its degradation or elevating its
synthesis (Jung et al., 2005). Interestingly, activation of Stat3 by IL-6
mediates expression of miR-17/92, resulting to the repression of
BMPRII protein (Brock et al., 2009), an important inhibitor of EC and
SMC proliferation. The translational interference of IL-6 to BMPRII
explains the difference only at the protein level of BMPRII but not at
the mRNA between Hypoxia and Hypoxia + SU.
IL-6 potentially regulated endothelin signaling in severe PAH
IL-6 enhances TGF-β-dependent Smad3 signaling (Zhang et al.,
2005). pSmad3 potentiates TGF-β-induced ET-1 from ECs (Castanares
et al., 2006; Rodríguez-Pascual et al., 2003, 2004). We demonstrated
that the increased TGF-β expression in Hypoxia and Hypoxia + SU
wasnot different, but pSmad3 expressionwas elevated only in the latter
group, which might indicate that pSmad3 contributed to the elevation
of ET-1 expression.
ETAR andETBR on the SMCsmediate the vasoconstriction and prolif-
eration of vascular SMCs (Davie et al., 2002; Kedzierski and Yanagisawa,
2001; Levin, 1995), while ETBR on the ECs induces the release of vasodi-
lator and anti-proliferative modulators. Furthermore, ETBR participates
in the clearance of ET-1 from the lungs and inhibition of endothelin
converting enzyme-1 (ECE-1) (Fukuroda et al., 1994; Naomi et al.,
1998). In patients with PAH, ET-1 plasma levels are elevated and corre-
lated with the severity and prognosis of the disease (Rubens et al.,
2001). ET-1 is particularly overexpressed in plexogenic lesions and
PAECs (Giaid et al., 1993). Similarly, we observed a high level of ET-1
mRNA in Hypoxia + SU. However, in hypoxia alone, ET-1 did not
change. Several researches indicate the positive (Kourembanas et al.,
1993; Perrella et al., 1992) or negative/neutral (Markewitz et al.,
1995) effect of hypoxia on ET-1 production. One reason cited by those
authors to explain the negative/neutral effect is the inhibitive role of
nitric oxide (NO) on ET-1 production of ECs. In hypoxic mice, we also
observed the increase of endothelial NO synthase (eNOS) gene expres-
sion in the hypoxic group (data not shown). In addition, we observed
an upregulation of ETARmRNA and protein in Hypoxia + SU. Immuno-
ﬂuorescence revealed the presence of ETAR on the SMCs, only in
Hypoxia + SU. Moreover, in vitro, IL-6 raised the mRNA ET-1 in
pmPECs and MS1, consistent with previous report showing that IL-6 is
a potent stimulator of ET-1 production by EC (Kahaleh and Fan, 1997).
This effect is dose dependent (Kahaleh and Fan, 1997), because low
dose of IL-6 (0.5–10 ng/ml) has no effect on ECs of the aorta, PA, and
retinal microvessels on the release of ET-1 (Kanse et al., 1991). This
is consistent with our results in mice under hypoxia alone showing
slightly elevated IL-6 and hence no change of ET-1. The up-regulation
of both ET-1 and ETAR may activate ERK1/2 inducing SMC proliferation
(Chen et al., 2009; Yogi et al., 2007; Zhang et al., 2003). Furthermore, we
noted ETBR reduction in vitro and in vivo. We have measured ET-1 ex-
pression at the mRNA level only. Nevertheless, we can speculate that
the reduced ET-1 clearance and ECE-1 inhibition consequent to a reduc-
tion of ETBR expression might potentiate ET-1 peptide abundance in
lungs of Hypoxia + SU mice. Since ETBR expression in SMC increases
in PAH (Bauer et al., 2002), the overall reduction of ETBR that we
observed might be underestimated in the ECs, which implies that the
vasodilation and antiproliferation mediated by ETBR on ECs might be
particularly down-regulated. This also might explain why selective
ETAR antagonist is not superior to non-selective ERA in human PAH
treatment (Benza et al., 2006; Christian et al., 2008).
Conclusion
We have optimized a model of severe PAH by using young SV129
mice and a combination of hypoxia and sustained VEGF-R inhibition.
These mice exhibited most important characteristics of severe PAHobserved in humans: concentric neointimal wall thickening, plexogenic
lesions, recruitment of macrophages, and distal arteriolar wall
muscularization. Using this model, we have demonstrated the role of
adventitia-derived IL-6 and recruited macrophages in adventitia of
remodeled vessels in the development of plexogenic lesions, suggesting
IL-6 in the adventitia as a potential therapeutic target. Moreover, we
produced evidences for a potential regulation of ET-1 signaling by IL-6
in the development of severe PAH. The cells in plexogenic sites were
proliferative ECs with high expression of VEGF, VEGF-R2, Bcl-2, and
HIF-1α, inferring the cancer-like features of PAH with excess prolifera-
tion and impaired apoptosis. These results may explain the difﬁculties
in treatment of severe human PAH with available drugs. Therefore,
this model can be reliable in investigating pathophysiological mecha-
nisms and testing new medications for treating severe PAH patients.Conﬂict of interest statement
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